尊龙Z6官方网站

12 November 2025, Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) today announced the appointment of Dr. Praveen Kudithipudi as a Business Development (BD) advisor. With over 20 years of extensive experience in the global biopharmaceutical industry, Dr. Praveen Kudithipudi’s appointment is expected to inject strong momentum in Abbisko Therapeutics’ global BD innovative strategy.

Dr. Kudithipudi brings more than two decades of experience in the biopharmaceutical sector, gaining deep expertise in business development, venture capital, incubation, competitive intelligence, portfolio management, investment banking and consulting with robust pipeline management and strategic planning skills. Over the past 10 years, he has led or participated in projects with a total disclosed value exceeding USD 3 billion, spanning multiple stages from early innovation to commercial collaboration. Currently, Dr. Kudithipudi serves as Chief Business Development Officer at BullFrog AI, and he has previously held senior roles at internationally renowned companies and institutions including Deep Genomics, Otsuka Pharma, and WestPark Capital.

In business development, Dr. Kudithipudi has successfully driven numerous high-value collaborations. Notably, he is a member of the BD team that licensed multiple central nervous system (CNS) products between Otsuka Pharma and Sumitomo Pharma, valued at USD 890 million. He introduced an IL-11 inhibitor biotech to a major Pharmaceutical company which later acquired the platform for payments that could reach up to USD 1 billion per product. Recently he successfully negotiated a collaboration agreement with Sygnature Discovery. These achievements highlight his outstanding global BD capability and strategic vision.

On the investment front, Dr. Kudithipudi has participated in more than 50 projects representing nearly USD 900 million in total funding. Three of these portfolio companies have successfully completed initial public offerings (IPOs), demonstrating his expertise in capital operations and industry enablement.

“We are very pleased to welcome Dr. Kudithipudi to Abbisko as our BD Advisor,” said Dr. Yao-Chang Xu, Founder and CEO of Abbisko Therapeutics. “His international perspective and extensive experience will be instrumental in advancing our global partnerships and accelerating the commercialization of our innovative drugs, strengthening Abbisko's competitive edge in global markets.”

About Abbisko Therapeutics

Founded in April 2016, Abbisko Therapeutics Co., Ltd. (HKEX: 02256.HK), is an oncology-focused biopharmaceutical company based in Shanghai that is dedicated to the discovery and development of innovative medicines to treat unmet medical needs in China and globally. The Company was established by a group of seasoned drug hunters with rich research & development and managerial expertise from top multinational pharmaceutical companies. Since its founding, Abbisko Therapeutics has built an extensive pipeline of innovative programs focused on precision oncology and immuno-oncology.

Please visit www.abbisko.com for more information.